Effect of Primary Intravitreal Bevacizumab Injection on Stage 3 Retinopathy of Prematurity with Plus Signs
Journal of the Korean Ophthalmological Society
;
: 62-69, 2015.
Artículo
en Coreano
| WPRIM
| ID: wpr-45182
ABSTRACT
PURPOSE:
To evaluate the efficacy and safety of primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs.METHODS:
We reviewed retrospectively the medical records of 30 eyes of 16 patients diagnosed with stage 3 retinopathy of prematurity with plus signs treated with primary intravitreal bevacizumab injection between March 1, 2011 and February 28, 2013 and followed up for at least 9 months.RESULTS:
Mean gestational age was 26 + 4 weeks +/- 11 days and mean birth weight was 822 +/- 251.4 g. The locations of disease were zone II in 24 eyes and zone III in 6 eyes. Intravitreal bevacizumab injection was performed after the mean 1.3 +/- 1 day after plus signs were detected. Mean postconceptional age at treatment was 38 + 2 weeks +/- 16 days. Mean follow-up period was 16.6 +/- 6.9 months. Plus signs started to regress after the mean 4.6 +/- 2.3 days after injection and completely regressed after the mean 24.3 +/- 12.4 days. Cataract extraction was performed in 1 eye due to a cataract that appeared not associated with the injection procedure, but was regarded as a treatment failure. There were no local or systemic complications.CONCLUSIONS:
Primary intravitreal bevacizumab injection in stage 3 retinopathy of prematurity with plus signs demonstrated excellent short-term efficacy and safety.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Peso al Nacer
/
Catarata
/
Retinopatía de la Prematuridad
/
Extracción de Catarata
/
Registros Médicos
/
Estudios Retrospectivos
/
Estudios de Seguimiento
/
Edad Gestacional
/
Insuficiencia del Tratamiento
/
Bevacizumab
Tipo de estudio:
Estudio diagnóstico
/
Estudio observacional
/
Estudio pronóstico
Límite:
Humanos
Idioma:
Coreano
Revista:
Journal of the Korean Ophthalmological Society
Año:
2015
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS